Evidence map›Paper›PMID 31337703›Full record

ArticleThe Journal of biological chemistry2019

A novel epitope-presenting thermostable scaffold for the development of highly specific insulin-like growth factor-1/2 antibodies.

Carmen Peeß, Christian Scholz, David Casagolda, Hartmut Düfel, Michael Gerg, Frank Kowalewsky, Marco Bocola, Leopold von Proff, Sabine Goller, Heidi Klöppel-Swarlik and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Carmen PeeßAntibody Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Christian ScholzProtein Design, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
David CasagoldaEnzyme & Protein Technologies, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Hartmut DüfelAntibody Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Michael GergAntibody Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Frank KowalewskyAntibody Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Marco BocolaLehrstuhl für Biotechnologie, RWTH Aachen University, 52074 Aachen, Germany.
Leopold von ProffEnzyme & Protein Technologies, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Sabine GollerEnzyme & Protein Technologies, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Heidi Klöppel-SwarlikEndocrinological Diseases III, Centralized and Point of Care, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Alessandra HoppeEndocrinological Diseases III, Centralized and Point of Care, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Michael SchrämlEnzyme & Protein Technologies, Roche Diagnostics GmbH, 82377 Penzberg, Germany. Electronic address: michael.schraeml@roche.com.
Roche Pharma AG (Germany) · DERWTH Aachen University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High sequence and structural homology between mature human insulin-like growth factors IGF-1 and IGF-2 makes serological discrimination by immunodiagnostic IGF tests a challenging task. There is an urgent need for highly specific IGF-1 and IGF-2 antibodies, yet only a short sequence element,

Indexed as

TemperatureAntibodies, MonoclonalEpitopesHumansInsulin-Like Growth Factor IInsulin-Like Growth Factor IIMolecular Dynamics SimulationAntibodies, MonoclonalEpitopesIGF1 protein, humanIGF2 protein, humanInsulin-Like Growth Factor IInsulin-Like Growth Factor IIantibodyantigen mimicantigen presentationchaperoneFK-506 binding proteinFKBP domainimmunogeninsulin-like growth factor (IGF)protein engineering

Identifiers

PMID31337703
PMCPMC6737233
OpenAlexW2963257274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.